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Background: Gastric disturbances such as dyspepsia are routinely encountered by multiple sclerosis (MS) patients,
and these conditions are often treated with gastric acid suppressors such as proton pump inhibitors, histamine H2
receptor antagonists, or antacids. The proton pump inhibitor omeprazole can alter the gut flora and immune
responses, both of which can influence the course of experimental autoimmune encephalomyelitis (EAE), an animal
model of MS. The objective of the current study was to examine the effect of omeprazole treatment on the
development of EAE. Bacterial microbiome analysis of mouse fecal pellets was determined in C57BL/6J EAE mice
chronically treated with omeprazole, and spleen immune cell content, clinical scores, weight, rotarod latency, and
histopathology were used as outcome measures in C57BL/6J and SJL/J mice with EAE.
Results: Omeprazole treatment resulted in decreases in Akkermansia muciniphila and Coprococcus sp. and an increase
in unidentified bacteria in the family S24-7 (order Bacteroidales) in C57BL/6J mice with EAE. Omeprazole did not alter
spleen immune cell content compared to vehicle in EAE mice, but differences independent of treatment were
observed in subsets of T cells between early and advanced disease in C57BL/6J mice as well as between the two
strains of mice at an advanced disease stage. Omeprazole caused no difference in clinical scores in either strain,
but significantly lowered weight gain compared to vehicle in the C57BL/6J mice with EAE. Omeprazole also did
not alter rotarod behavior or hindbrain inflammatory cell infiltration compared to vehicle in both strains of mice
with EAE. Rotarod latency did reveal a negative correlation with clinical scores during active disease in both
mouse strains, but not during clinical remission in SJL/J mice, suggesting that rotarod can detect disability not
reflected in the clinical scores.
Conclusions: Despite alterations in the gut microbiota and weight gain in the C57BL/6J EAE model, omeprazole
had no effect on multiple measures of disease activity in C57BL/6J and SJL/J mice with EAE, supporting the
notion that omeprazole does not substantially influence disease activity in MS patients.
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Gastric disturbances are commonly encountered in mul-
tiple sclerosis (MS) patients, with ~30% reporting prob-
lems with dyspepsia [1]. Many of these disturbances are
treated with gastric acid suppressors such as proton
pump inhibitors (PPI), histamine H2 receptor antago-
nists, or antacids. These gastric acid suppressors are
widely used, available over the counter, and generally* Correspondence: slevine@kumc.edu
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unless otherwise stated.considered safe; however, there have been concerns
about susceptibility to small intestinal bacterial over-
growth [2] and enteric infections [3]. Since the gut
microflora has been shown to influence the disease
course in experimental autoimmune encephalomyelitis
(EAE) [4-6], an animal model of MS, a PPI could theor-
etically impact disease progression by altering the micro-
biota. In addition, PPIs can directly affect the immune
response [7], raising the possibility of a second mechan-
ism of action by PPIs on disease progression. The object-
ive of this study was to evaluate the effect of omeprazole
treatment on the development of EAE in the C57BL/6Jtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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remitting MS.
Methods
Animal handling and housing
All studies involving the use of animals were approved
by the Institutional Animal Care and Use Committee
of the University of Kansas Medical Center. Female
C57BL/6J and female SJL/J mice (Jackson Laboratory,
Bar Harbor, ME) were used for EAE induction. Animals
were maintained on standard rodent chow (8604 Teklad
rodent diet, Harlan, Indianapolis, IN), had water avail-
able ad libitum, and were maintained on a 12/12 h
light/dark cycle. C57BL/6J mice were given 31M Nutri-
gel (ClearH2O, Portland, ME) supplementation as mice
started to develop advanced disease, with all mice on
Nutrigel by Day 27 post-encephalitogen injection. SJL/J
mice that developed advanced disease, and their cage
mates, received supplementation with DietGel Recovery
Nutrigel (ClearH2O).
EAE induction - C57BL/6J mice
EAE was induced in ~5 week old C57BL/6J female mice
(Jackson Laboratory). Two studies were conducted; the
first study lasted until Day 18 post-encephalitogen,
the point at which disease was first detected (early
clinical), while the second study lasted until Day 46 post-
encephalitogen, at which point most mice were in an ac-
tive disease stage of EAE, i.e., clinical disability. For both
studies, mice were anesthetized with isoflurane (Abbott
Labs, North Chicago, IL), dorsal surface shaved, and
given two subcutaneous injections (dorsum) of the en-
cephalitogen myelin oligodendrocyte glycoprotein pep-
tide [amino acids 35-50; 250 μg (1st study) or 300 μg
(2nd study)] with emulsion [Freund’s incomplete adjuvant
containing 250 μg (1st study) or 500 μg (2nd study)
Mycobacterium tuberculosis (Difco Laboratories, Detroit,
MI)]. Once completed, an intraperitoneal (i.p.) injection of
pertussis toxin (PTX; 100 ng/100 μl saline; List Biological
Laboratories, Campbell, CA) was administered. Mice were
given one (1st study- Day 3 post-encephalitogen injection)
or two (2nd study- Day 3 and 7 post-encephalitogen injec-
tion) additional PTX injections. Mice were weighed on
Day 0 and 7 post-encephalitogen, and every day thereafter,
and scoring began on Day 9 post-encephalitogen. Mice
were scored using a modified 0-8 point scale from that
described previously [8]. A 0-8 point scale offers greater
sensitivity to detect statistical differences between groups
compared to 0-5 scales, or has a similar sensitivity to 0-5
scales that include some half point differences. Briefly, the
scoring system was as follows: 0 = normal; 1 = flaccid/limp
tail; 2 = hindlimb weakness causing righting difficulty from
a supine position; 3 = hindlimb weakness causing righting
inability ≥ 8 sec from a supine position; 4 = hindlimbweakness causing limping and abnormal gait; 5 = partial
(one limb) hindlimb paralysis or extensive hindlimb weak-
ness such that the hindlimbs cannot contribute to mobility;
6 = total (both) hindlimb paralysis plus forelimb weakness;
7 = hindlimb paralysis and forelimb weakness or paralysis
resulting in a side resting position; 8 =moribund requiring
sacrifice or inadvertent death. Omeprazole (Premier
Pharmacy Labs, Weeki Wachee, FL) (15 mg/kg, i.p., twice
daily) and saline administration began on Day 8 post-
encephalitogen. Spleens were harvested in both studies for
flow cytometry. Fecal pellets for bacterial analyses were
collected in the 2nd study on Day 40 post-encephalitogen
injection. Hindbrains were immersion-fixed in 10% neutral
buffered formalin (Fisher Scientific, Hanover Park, IL) and
paraffin-embedded.
EAE induction - SJL/J mice
EAE was induced in ~5-6 week old SJL/J female mice
(Jackson Laboratory). Mice were anesthetized with iso-
flurane (Abbott Laboratories), dorsal surface shaved, and
given two subcutaneous injections (dorsum) of encepha-
litogen [150 μg proteolipid protein peptide (amino acids
139-151)] with emulsion [Freund’s incomplete adjuvant
containing 250 μgM. tuberculosis (Difco Laboratories)].
This was followed with an i.p. injection of PTX. Mice were
also administered PTX on Day 3 post-encephalitogen
injection.
Mice were weighed at Day 0 and 7 post-encephalitogen
administration and every day thereafter. Clinical scoring
was performed as described previously [8] except the
standard for a score of 5 described above was used.
Administration of omeprazole (15 mg/kg, i.p., twice daily)
or saline began when a score of 1 was first detected
(beginning of active disease) and continued until sac-
rifice. On Day 15 post-encephalitogen injection, which
was a peak of disease activity, a matched subset of 5 mice
within each group was sacrificed and hindbrains and
spleens harvested for histopathology and flow cytometry,
respectively. The remaining mice were sacrificed on Day
22 or later post-encephalitogen injection.
Bacterial analysis
Sample collection & DNA extraction
On Day 40 post-encephalitogen, two freshly evacuated
fecal pellets were collected per C57BL/6J mouse with
EAE given omeprazole or saline. Pellets were placed into
a microcentrifuge tube and immediately frozen on dry
ice. Microbiome analysis was performed by the Mutant
Mouse Regional Resource Center (University of Missouri-
Columbia) where the pellets were transferred to 2 mL
round-bottom tubes containing 800 μL lysis buffer
(500 mM NaCl, 50 mM Tris-HCl, 50 mM EDTA, and
4% sodium dodecyl sulfate) and a 0.5 cm diameter
stainless steel bead. Following mechanical disruption using
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cubated at 70°C for 20 min with brief vortexing every
5 min. Samples were then centrifuged at 5000 × g for
5 min at room temperature, and the supernatant trans-
ferred to a clean 1.5 mL Eppendorf tube. Ammonium
acetate (10 mM; 200 μL) was added to lysates, mixed thor-
oughly, incubated on ice for 5 min, and centrifuged at
5000 × g for 5 min at room temperature. The super-
natant, 750 μL, was mixed with one volume of chilled
isopropanol, mixed thoroughly, incubated on ice for
30 min, and centrifuged at 16000 × g for 15 min at 4°C.
The supernatant was aspirated and discarded, and the
DNA pellet was washed several times with 70% EtOH
and resuspended in 150 μL of Tris-EDTA. Proteinase-K
(15 μL) and Buffer AL (200 μL) (Qiagen DNeasy kit,
Qiagen) were added and incubated at 70°C for 10 min,
followed by addition of 200 μL of 100% EtOH. The con-
tents of each tube were transferred to a spin column
from the DNeasy kit. DNA was purified according to the
manufacturer’s instructions and eluted in 200 μL of EB
buffer. Purity of DNA was assessed via spectropho-
tometry (Nanodrop, Thermo Fisher Scientific, Waltham,
MA); yield was determined via fluorometry (Qubit, Life
Technologies, Carlsbad, CA) using quant-iT BR dsDNA
reagent kit (Invitrogen).
Metagenomic library preparation and sequencing
Extracted fecal DNA was processed at the University of
Missouri DNA Core Facility. Bacterial 16S ribosomal
DNA amplicons were constructed by amplification of
the V4 hypervariable region of the 16S rRNA with
primers flanked by Illumina standard adapter sequences.
Briefly, universal primers (U515F/806R), previously de-
veloped against the V4 region, were used for generating
amplicons [9,10]. Oligonucleotide sequences are avail-
able at proBase [11]. A single forward primer and re-
verse primers with a unique 12-base index were used in
all reactions. Extracted DNA was quantitated by Qubit
fluorometer using the quant-iT HS dsDNA reagent kit
(Invitrogen). PCR reactions (50 μL) contained 100 ng of
genomic DNA, forward and reverse primers (0.2 μM
each), dNTPs (200 μM each), and Phusion High-
Fidelity DNA Polymerase (1U). PCR amplification was
performed as follows: 98°C(3:00) + [98°C(0:15) + 50°C(0:30) +
72°C(0:30)] × 25 cycles +72°C(7:00). Amplified product
(5 μL) from each reaction was combined and thoroughly
mixed; pooled amplicons were purified by addition of
Axygen AxyPrep MagPCR Clean-up beads (50 μL) to an
equal volume of 50 μL of amplicons and incubated at
room temperature for 15 min. Products were washed mul-
tiple times with 80% EtOH and the dried pellet resus-
pended in Qiagen EB Buffer (32.5 μL), incubated at room
temperature for 2 min, and then placed on the magnetic
stand for 5 min. Supernatant (30 μL) was transferredto low binding microcentrifuge tube for storage. The
final amplicon pool was evaluated using the Advanced
Analytical Fragment Analyzer automated electrophoresis
system, quantified with the Qubit fluorometer using the
quant-iT HS dsDNA reagent kit (Invitrogen), and diluted
according to Illumina’s standard protocol for sequencing
on the MiSeq.
Informatics analysis
Assembly, binning, and annotation of DNA sequences
were performed at the MU Informatics Research Core
Facility. Briefly, contiguous sequences of DNA were as-
sembled using FLASH software [12], and Qiime v1.7
[13] was used to select representative operational taxo-
nomic units (OTUs). Taxonomy was assigned to selected
OTUs using BLAST [14] against the Greengenes data-
base [15] of 16S rRNA sequences and taxonomy.
Flow cytometry
Spleens were minced using a wire mesh, and spleno-
cytes were collected and counted. For the immuno-
detection of specific populations of T cells within the
spleen, anti-CD4-Pacific Blue, anti-CD8-Alexa647, anti-
CD24-PE, anti-CD44-PE-Cy5.5, and anti-CD62L-PE-Cy7
were purchased from BioLegend (San Diego, CA) or BD
Biosciences (San Jose, CA). Cell labeling was performed
in PBS containing 2% FCS. Flow cytometry studies were
performed using a BD LSR II (BD Immunocytometry
Systems, San Jose, CA). Data were analyzed using BD
FACSDiva software (BD Biosciences). Splenocytes were
gated on the live lymphocyte gate and doublet dis-
crimination was performed. Naïve T cells were defined
as CD44loCD62Lhi, central memory (CM) T cells as
CD44hiCD62Lhi, and effector memory (EM) T cells as
CD44hiCD62Llo.
Rotarod
The rotarod was set to accelerate from a speed of 4
to 40 rotations per minute in a 300 second time trial.
Each mouse was given an exposure trial to familiarize
the animal to the task, and this initial trial was not
included for data analysis. Each animal was then given
two trials and the times at which mice could no lon-
ger successfully manage or remain on the rotarod
(rotarod latency) were averaged and analyzed for dif-
ferences between treatment groups and relationships
to EAE clinical scores.
Histopathology
Following paraffin embedding, sagittal sections of the
hindbrain were cut at 8 μm thickness and processed for
hematoxylin and eosin staining. Sections were evaluated
on the basis of number of lesions and magnitude of
lesions present in the hindbrain.
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The two-tailed Student’s t-test was used to evaluate
weight change, difference in absolute numbers of sub-
sets of spleen cells, and rotarod latency between omep-
razole and saline groups. The Wilcoxon two sample
test was employed to evaluate percent differences in
bacterial microbiota, percent CD4+ and CD8+ spleen
cells, max clinical scores, and area under the curve
(sum clinical scores) between groups. Statistical signifi-
cance was set at p ≤ 0.05 for both the Student’s t-test
and the Wilcoxon two sample test. For regression ana-
lysis between clinical score and rotarod latency, the r2
value and statistical significance (p ≤ 0.05) were evaluated
using GraphPad Prism 6 software (GraphPad Software,
Inc., San Diego, CA).
Results
Omeprazole affects the gut microbiota in C57BL/6J mice
with EAE
The gut microflora has been shown to affect EAE dis-
ease progression [4-6]. Since omeprazole can elevate the
gastric pH [16], which could affect the growth of popula-
tions of bacteria in the gut [17], omeprazole has the po-
tential to affect the progression of EAE. We first sought
to determine the effect of chronic omeprazole treatment
on the bacterial gut microbiota in C57BL/6J mice with
EAE. Shifts in percentages of specific bacteria popula-
tions were identified following omeprazole treatment
(Figure 1A, B); in particular, there were significant de-
creases in Akkermansia muciniphila and Coprococcus sp.
and an increase in unidentified microbes in the family
S24-7 (order Bacteroidales), which was the most abun-
dant OTU in the fecal samples (Figure 1C-E; Additional
file 1: Table S1). There were numerous different bacterial
taxa detected (Figure 1A, B; Additional file 1: Table S1),
but there was no significant difference in their relative
abundance between the omeprazole and saline EAE
mice, or they represented < 0.1% of the total bacterial
population.
Omeprazole does not affect spleen T cell content in
C57BL/6J mice with EAE
Since the spleen is a key site of T cell activation and has
a prominent role in the development of EAE [18],
the effect of omeprazole on spleen T cell populations
was examined. T cells collected at an early clinical stage
(Day 18) or during an active disease stage (Day 46) dis-
played no differences between omeprazole and vehicle
administration (Figure 2A-D). However, there was a dif-
ference in the spleen immune cell populations between
these different stages of disease progression. There were
statistically significant higher numbers of EM CD4+
T cells, CM CD4+ T cells, EM CD8+ T cells, and CM
CD8+ T cells, and lower numbers of naïve CD4+ T cell andCD8+ T cells in the advanced disease stage compared to
the early clinical stage (Additional file 2: Figure S1A).
Omeprazole does not affect clinical or pathological signs
in C57BL/6J mice with EAE
The first detection of EAE disease activity in most
C57BL/6J mice was approximately 18 days or greater
post-encephalitogen injection, about the time at which
they were ~7 ½ weeks old, although occasionally a low
percentage of mice became sick earlier. This delayed on-
set compared to other studies was likely due to injection
of the encephalitogen into ~5 week old C57BL/6J mice
rather than older C57BL/6J mice used in other studies
[6,19]. After disease onset, the progression of clinical
scores appeared to advance more rapidly in the EAE
mice administered omeprazole compared to saline, but
the differences did not achieve significance (Figure 3A).
However, the differences in weight were significant (less
weight gain) in the omeprazole group vs. the saline group
(Figure 3B). No differences were observed in rotarod la-
tency between groups receiving omeprazole and saline
administration during any stage of EAE disease progres-
sion (Day 14, 25 or 40 post-encephalitogen injection)
(Figure 3C-E), and thus, data were pooled for compari-
sons of rotarod latency and clinical scores. Comparison
of the relationship between rotarod latency and clinical
scores revealed that at Day 14 and Day 25 the two clinical
measures did not correlate well (Figure 3C, D); but
by Day 40, there was a strong correlation between
rotarod latency and clinical scores (r2 = 0.747, p < 0.005;
Figure 3E). Inflammatory cell infiltrates were present in
the hindbrains of both omeprazole and saline treated mice
during active disease, but there was no major difference
between treatment groups (Figure 3F, G).
Omeprazole does not affect EAE disease activity in SJL/J mice
On average, EAE in SJL/J mice was first detected by ~10
days post-encephalitogen. Administration of omepra-
zole or saline was started at the initiation of clinical
signs (Day 0 of treatment). Examination of the im-
mune cell content in spleens during active disease re-
vealed that administration of omeprazole did not alter
the T cell content compared to saline (Figure 4A, B).
Furthermore, there was no difference in the clinical
disease profile between omeprazole and saline admin-
istered mice with EAE, i.e., both groups developed ad-
vanced disease (e.g., clinical score of 6 or 7 and
substantial weight loss) which was followed by remis-
sion (e.g., clinical scores dropping to ~2 associated with
weight gain) (Figure 4C, D). There was also no significant
difference in rotarod behavior between mice adminis-
tered omeprazole or saline during active disease or re-
mission (Figure 4E, F), and thus the data were pooled
between groups for comparisons of rotarod latency and
Figure 1 Next-generation sequencing of fecal microbiota from omeprazole and saline treated C57BL/6J mice. Pellets were collected on
Day 40 post-encephalitogen during active disease from a subset of omeprazole (n = 5) and saline (n = 5) treated C57BL/6J mice. Sequences were
annotated against a database of known 16S rRNA gene sequences and binned at all taxonomic levels (phylum, class, order, etc.). Operational
taxonomic units (OTUs) represented in these graphs were statistically different following omeprazole treatment in C57BL/6J mice. Overall
distribution in saline (A) and omeprazole (B) treated mice and more detailed analyses of three different OTUs (C-E) are shown. Black bars - saline
treatment; white bars - omeprazole treatment. Additional information is provided in Additional file 1: Table S1.
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clinical score and rotarod latency during active disease
(r2 = 0.653, p < 0.005; Figure 4E), but not during remis-
sion (Figure 4F) in SJL/J mice, at which point a hetero-
geneity in rotarod latency was revealed despite most
mice displaying a similar clinical score of 2 (Figure 4F).
Both omeprazole and saline treated EAE mice dis-
played an abundance of inflammatory cell infiltrates
in the hindbrain (data not shown).
Comparisons of the spleen T cell content between the
two strains of mice with active EAE revealed that total
and naïve CD4+ and CD8+ cells were significantly higher
in SJL/J mice than in C57BL/6J mice, and there were
more CM CD4+ and CD8+ T cells in the C57BL/6J EAE
mice compared to SJL/J EAE mice (Additional file 2:
Figure S1B).Discussion
The gut microflora can affect EAE disease progression
[4-6]. For instance, segmented filamentous bacteria [6],
likely from the genus Clostridium [20], were found to
augment EAE while Bacteroides fragilis limits EAE de-
velopment [21]; and depending on the species of Lacto-
bacillus, EAE disease activity can be increased [22] or
ameliorated [23]. In our study, Clostridium was not sig-
nificantly different between treatments (0.18 ± 0.13 sa-
line; 0.22 ± 0.11 omeprazole), and Bacteroides fragilis
and Lactobacillus sp. were below 0.1% in both groups
(saline or omeprazole) of EAE mice. Thus, omeprazole
treatment did not appear to substantially affect gut bac-
teria currently known to influence EAE development.
Akkermansia muciniphila was significantly lower in
the omeprazole treated EAE mice compared to vehicle
Figure 2 Evaluation of spleen immune cell content in omeprazole and saline treated C57BL/6J mice. Quantitation of spleen immune cells
from flow cytometry analysis in saline and omeprazole treated C57BL/6J mice was performed on Day 18 post-encephalitogen (A, B), which was
at an early clinical stage (clinical scores: saline 2.36 +/- 0.84, n = 7 vs. omeprazole 1.21. +/- 0.15, n = 7; p = 0.15) and Day 46 post-encephalitogen
(C, D), which was during an advanced disease stage (clinical scores: saline 4.14 +/- 0.7, n = 7 vs. omeprazole 4.14 +/- 0.14, n = 7; p = 1.0). No
differences in the percent of naïve (CD44loCD62Lhi), CM (CD44hiCD62Lhi) or EM (CD44hiCD62Llo) CD4+ or CD8+ cells (from parent CD4+ or
CD8+ populations) were observed following omeprazole treatment vs. saline during both stages of EAE. Black bars, saline treatment; white bars,
omeprazole treatment.
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lytic bacterium that is found in the mucus layer of the
large intestine [24]. Omeprazole has been shown to in-
hibit mucin production by the stomach [25,26]. Thus, a
lower production of mucins following omeprazole treat-
ment likely made it difficult for Akkermansia mucini-
phila to thrive, which could account for the significantly
diminished levels of Akkermansia muciniphila following
omeprazole treatment. Low levels of Akkermansia muci-
niphila have been associated with obesity and type 2 dia-
betes in C57BL/6J mice [27]. However, in the present
study, EAE mice given omeprazole had less weight gain,
despite a lower percentage of Akkermansia muciniphila,
compared to EAE mice given saline. The findings with
the unidentified OTU in order Bacteroidales, family
S24-7 might better explain the weight changes.
The relative abundance of this OTU (order Bacteroi-
dales, family S24-7) increased in the present study fol-
lowing omeprazole treatment. An increased level of this
taxon has been observed following exercise [28] and in
lean mice compared to obese mice [29]. Our study did
not measure absolute levels of bacteria, but rather evalu-
ated the relative abundance of different types of bacteria.
However, bacterial overgrowth can occur in the stomachand duodenum following omeprazole treatment [17],
and bacterial growth and gastric acid suppressors have
both been associated with weight loss in the elderly [30].
Thus, it may not be surprising that omeprazole treated
EAE mice had less weight gain than saline treated EAE
mice.
The percentage of Coprococcus sp. decreased following
omeprazole treatment. Little is known about the genus
Coprococcus relative to EAE. Its abundance is increased
in Crohn’s disease [31] and is decreased following expos-
ure to social disruption stress [32] or in HIV individuals
not taking combination anti-retroviral therapy [33].
Besides affecting the gut microbiota, PPIs have been
shown to affect neutrophil function, which recently has
been implicated to play a role in disease initiation in
EAE [34,35]. In particular, omeprazole can decrease the
migration, bactericidal activity, and oxygen-derived free
radical production by neutrophils [36-38]. PPIs can also
affect NK cells [39] and monocytes [40]. However, MS
and EAE are primarily T cell driven diseases [41-47]. It
is unknown whether omeprazole directly affects T cells,
but the PPI esomeprazole was thought to create a micro-
environment, via a change in pH, more suitable for T
cell activity against tumors [48]. In the present study,
Figure 3 Comparison of omeprazole and saline treated C57BL/6J mice with EAE. Average clinical scores (A) revealed no significant
differences between groups, but weight differences (B) revealed that omeprazole treated EAE mice (n = 12) had significantly less weight gain
relative to Day 7 than saline EAE mice (n = 12). Rotarod latency at Day 14 (C), Day 25 (D), and Day 40 (E) post-encephalitogen, with no differences
observed between omeprazole and saline groups. A strong negative correlation was observed between clinical score and rotarod latency during
active disease at Day 40 post-encephalitogen (r2 = -0.747, p < 0.005), but not at Day 14 or Day 25. Black squares, saline treatment; white squares,
omeprazole treatment. Histological examination revealed no major differences in inflammatory cell infiltrates in the hindbrains of both saline (F)
and omeprazole (G) C57BL/6J mice during active disease. Bar = 50 μm.
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subsets of T cells (e.g., CM, EM) in the spleen of
C57BL/6J or SJL/J EAE mice. Furthermore, omepra-
zole did not affect relative levels of inflammatory cell
infiltrates in the hindbrain, which are largely com-
posed of T cells, in either strain, although it is pos-
sible that omeprazole could affect other components
of the T cell response.Aside from differences in weight gain in C57BL/6J
EAE mice, omeprazole did not affect other clinical mea-
sures of disease activity, i.e., clinical scores and rotarod
latency, in either C57BL/6J or SJL/J EAE mice. Inde-
pendent of treatment, rotarod latency did not appear to
correlate with clinical scores during the preclinical or
early stage of EAE in C57BL/6J mice, but a strong cor-
relation was present in animals with active disease, and
Figure 4 Evaluation of omeprazole and saline treated SJL/J mice with EAE. Quantitation of percent of naïve, CM or EM CD4+ or CD8+ cells
(relative to respective parent CD4+ or CD8+ populations) was performed on spleen cells from saline (n = 5) and omeprazole (n = 5) treated SJL/J
mice during active disease (A, B). No significant differences were observed following omeprazole treatment compared to saline in the relative
percentages of all T cell populations examined. Average clinical scores (C) and weight difference from the day prior to disease onset (D) in saline
and omeprazole treated SJL/J mice. No significant differences were observed between groups (n = 15 for the omeprazole group and n = 16 for
the saline group at the start of the study, with 5 mice per group sacrificed at Day 15 and used for splenocyte analysis, above). Rotarod latency
plotted vs. clinical scores during active disease, Day 14 post-encephalitogen (E) and remission, Day 21 post-encephalitogen (F). No differences
were observed following omeprazole treatment vs. saline at either disease stage. A negative correlation was observed between clinical score and
rotarod latency on Day 14 post-encephalitogen (r2 = -0.653, p < 0.005).
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active disease. However, once the SJL/J mice entered
into remission, based on clinical signs, the correlation
was lost. For example, almost all the SJL/J mice had a
clinical score of 2 during remission, yet there was a wide
heterogeneity in rotarod latency values which did not
appear to correlate to a prior maximum clinical score or
with hindbrain pathology (i.e., inflammatory cell infil-
trates). Thus, rotarod testing revealed that mice in re-
mission had a range of persistent deficiencies that were
not reflected in the clinical score. Therefore, we suggest
that rotarod latency can be a useful measure to comple-
ment clinical scoring for disease assessment, particularly
during later stages of disease. Interestingly, the ex-
panded disability status scale has quantitative measuresof mobility included in the evaluation of disease status in
MS patients [49]; thus, including both clinical scores and
rotarod latency for measurement of EAE activity would
more closely align the evaluations used for human and
rodent studies.
Th1 CD4+, CD8+ and/or Th17 T cells are important
contributors to disease activity in EAE and MS [41-47].
The spleen T cell population changed during different
stages of disease in C57BL/6J mice. A decrease of naïve
CD4+ and CD8+ cells was associated with an increase in
both EM and CM CD4+ and CD8+ cells during active
disease compared to early disease. Furthermore, the total
number of CD4+ and CD8+ spleen cells were increased
during active disease. These changes likely reflect the
heightened activation of the immune system during active
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T cells affect the development of EAE [50].
During active disease, a higher percentage of naïve
CD4+ and CD8+ and a lower percentage of CM CD4+
and CD8+ cells and EM CD8+ cells were observed in
SJL/J mice compared to C57BL/6J mice. There was also
a difference in the absolute cell counts in the spleen
of the two strains, with SJL/J having nearly twice as
many cells as the C57BL/6J. These differences are likely
accounted for by apoptosis and spleen atrophy, which
have been observed in spleens of mice with progressive
EAE, but not with relapsing-remitting EAE [51].
An observation during the procedures used for this
study was that defecation appeared less frequent in EAE
mice with advanced disease compared to healthier mice,
regardless of treatment. This may have been due to a
difference in food consumption or a disruption of ner-
vous control over peristalsis and/or defecation as EAE
progressed; of note, bowel dysfunction occurs in a large
percentage of MS patients, which can be due to a variety
of causes [52].
Conclusions
Although there was a difference in the microbiota and
weight gain in the C57BL/6J EAE model, omeprazole had
no effect on spleen T cell populations, clinical scores,
rotarod, and histopathology in C57BL/6J and SJL/J EAE
mice. Thus, omeprazole does not appear to have a positive
or negative effect on the disease course of EAE, suggesting
that omeprazole may not be affecting disease activity in
MS patients. However, despite testing in two EAE models,
the design used in the present study has limitations relative
to applicability to humans. Besides the obvious limitation
of extrapolating results from mice with EAE to humans
with MS, the gut microbiota in each individual is a result
of multiple factors; thus, it is theoretically possible that in
specific situations a PPI could cause a shift in the micro-
biota, or other factor, that influences MS disease activity.
As we learn more about the influences of the gut micro-
flora on MS disease activity, it might become relevant to
revisit the role of PPIs in MS.
Additional files
Additional file 1: Table S1. Operational taxonomic units.
Additional file 2: Figure S1. Since there were no clear differences
between saline and omeprazole treatment in the percent of naïve, CM or
EM CD4+ or CD8+ cells (from parent CD4+ or CD8+ populations)
(Figure 2), mice from the omeprazole and saline groups were pooled and
used to analyze the differences in immune cell populations between the
two different stages of EAE in C57BL/6J mice (clinical scores at Day 18 vs.
Day 46, p = 0.0009) using absolute numbers of the total spleen cell
population (A). More CM and EM CD4+ and CD8+ were observed at
the advanced disease stage and more naïve CD4+ and CD8+ cells
were observed during the early clinical stage (* p < 0.05; ** p < 0.001;
*** p < 0.00001). Comparison of spleen cells from SJL/J mice withactive disease (Day 15) and C57BL/6J mice with active disease (Day 46)
(B). Since there were no clear differences between saline and omeprazole
treatment, mice from the omeprazole and saline groups were pooled to
analyze the differences in immune cell populations between the two
different strains of EAE using absolute numbers of the total spleen cell
population. More CM and EM CD8+ cells and more CM CD4+ cells were
observed in C57BL/6J mice compared to SJL/J mice with active disease
(* p < 0.01; ** p < 0.000001). Conversely, fewer total and naïve CD4+
and CD8+ cells were observed in C57BL/6J mice compared to SJL/J
mice with active disease (** p < 0.000001). Black bars or squares, saline
treatment; white bars or squares, omeprazole treatment.
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